BD BBL Sensi Disc Cefaclor - 30 ug¿, used for semi-quantitative in vitro susceptibility testing. ...

FDA Device Recall #Z-1017-2024 — Class II — January 8, 2024

Recall Summary

Recall Number Z-1017-2024
Classification Class II — Moderate risk
Date Initiated January 8, 2024
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Becton Dickinson & Co.
Location Sparks, MD
Product Type Devices
Quantity 2,363,168 total units

Product Description

BD BBL Sensi Disc Cefaclor - 30 ug¿, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231653¿

Reason for Recall

There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Distribution Pattern

Domestic distribution nationwide. International distribution worldwide.

Lot / Code Information

Catalog No. 231653¿ UDI-DI 30382902316535 Lots 1085898 1273095 1273096 2004485 2147706 2333108

Other Recalls from Becton Dickinson & Co.

Recall # Classification Product Date
Z-0484-2026 Class II BD Kiestra" Isolate Suspension Cuvette Array; ... Oct 23, 2025
Z-0235-2026 Class II BD EpiCenter Microbiology Data Management Syste... Sep 23, 2025
Z-0236-2026 Class II BD BACTEC Blood Culture System, labeled as the ... Sep 23, 2025
Z-0240-2026 Class II BD Veritor Connect Software, labeled as the fol... Sep 23, 2025
Z-0237-2026 Class II BD BACTEC Blood Culture System, labeled as the ... Sep 23, 2025

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.